Funding Details
- Awarder
- Inbox
- Date Award
- June 21, 2024
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Premoney Valuation
-
$1,000,000
- Valuation
-
$53,000,000
Company Info
- Founding Year
- Unknown
- Traction
- PhorMed has shown promising results with their drug in clinical trials, including high success rates in remission, tumor reduction, and inflammation reduction. They have a strong investor base and are advancing towards Phase 2 trials.
- Organizations Involved
- Unknown
- Founders
- Ben Chang, Richard L. Chang, Carole A. Salvador
- Company Description
- PhorMed is on a mission to bring new hope and a brighter future to patients battling life-threatening diseases. They have raised $3.5 million from over 4,100 investors through crowdfunding and angel investors. Their drug, RP-323, repairs damaged cells and kills cancer. PhorMed is positioned as undervalued with the potential to buy low and sell high compared to similar companies valued between $290M-1.2B.
- Market
- Healthcare
- Location
-
Unknown,
Unknown,
US
- Coinvestors
- Edward Pan, James Charleston
Links